Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study

Journal of Clinical Pathology

Volumn 65, Issue 3, 2012, Pages 218-223

  Sartore Bianchi, Andrea ^a   Fieuws, Steffen ^b   Veronese, Silvio ^a   Moroni, Mauro ^a   Personeni, Nicola ^c   Frattini, Milo ^d   Torri, Valter ^e   Cappuzzo, Federico ^c   Vander Borght, Sara ^f   Martin, Vittoria ^d   Skokan, Margaret ^g   Santoro, Armando ^c   Gambacorta, Marcello ^a   Tejpar, Sabine ^f   Varella Garcia, Marileila ^g   Siena, Salvatore ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b KU LEUVEN   (Belgium)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d INSTITUTE OF PATHOLOGY   (Switzerland)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CHROMOSOME 7; COLORECTAL CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; MOLECULAR DIAGNOSIS; NUMERICAL CHROMOSOME ABERRATION; POLYSOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCIBILITY; SCORING SYSTEM; STANDARDIZATION;

CHROMOSOMES, HUMAN, PAIR 7; CLINICAL LABORATORY TECHNIQUES; COLORADO; COLORECTAL NEOPLASMS; EUROPE; GENE DOSAGE; GUIDELINE ADHERENCE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; OBSERVER VARIATION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857366043     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200353     Document Type: Article

References (29)

1. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
2. Winer E, Gralow J, Diller L, et al American Society of Clinical Oncology. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screeningda report from the American Society of Clinical Oncology. J Clin Oncol 2009;27:812-26.
3. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
4. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
5. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as firstline treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
6. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9. (Pubitemid 351171687)
7. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86. (Pubitemid 40590264)
8. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
9. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009;4:e7287.
10. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20.
11. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009;101:1308-24.
12. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-30.
13. Scartozzi M, Bearzi I, Mandolesi A, et al. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan cetuximab in K-RAS wildtype colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009;9:303.
14. Li YH, Wang F, Shen L, et al. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. Clin Cancer Res 2011;17:382-90.
15. Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patientderived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery. Published Online First: 2 September 2011. doi:10.1158/2159-8290.CD- 11-0109.
16. Moroni M, Sartore-Bianchi A, Veronese S, et al. EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol 2008;9:402-3. (Pubitemid 351597789)
17. Martin V, Mazzucchelli L, Frattini M. An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol 2009;62:314-24.
18. Varella-Garcia M, Diebold J, Eberhard DA, et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 2009;62:970-7.
19. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97:1139-45. (Pubitemid 47587019)
20. Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008;14:5869-76.
21. Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008;19:717-23. (Pubitemid 351461042)
22. Quan H, Shih WJ. Assessing reproducibility by the within-subject coefficient of variation with random effects models. Biometrics 1996;52:1195-203. (Pubitemid 26425271)
23. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25:3238-45. (Pubitemid 47325607)
24. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904. (Pubitemid 38993773)
25. Sauer T, Guren MG, Noren T, et al. Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy? Histopathology 2005;47:560-4. (Pubitemid 41775177)
26. Spindler KL, Lindebjerg J, Nielsen JN, et al. Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods. Int J Oncol 2006;29:1159-65.
27. Ramieri MT, Murari R, Botti C, et al. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. Anticancer Res 2010;30:1287-92.
28. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21. (Pubitemid 46630920)
29. Shia J, Klimstra DS, Li AR, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 2005;18:1350-6. (Pubitemid 41348654)